Abstract：
The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of the KDIGO 2020 guideline on the topic. The guideline targets a broad audience of clinicians treating people with diabetes and CKD. Topic areas for which recommendations are updated based on new evidence include Chapter 1: Comprehensive care in patients with diabetes and CKD and Chapter 4: Glucose-lowering therapies in patients with type 2 diabetes (T2D) and CKD. The content of previous chapters on Glycemic monitoring and targets in patients with diabetes and CKD (Chapter 2), Lifestyle interventions in patients with diabetes and CKD (Chapter 3), and Approaches to management of patients with diabetes and CKD (Chapter 5) has been deemed current and was not changed. This guideline update was developed according to an explicit process of evidence review and appraisal. Treatment approaches and guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence, and the strength of recommendations followed the \"Grading of Recommendations Assessment, Development and Evaluation\" (GRADE) approach. Limitations of the evidence are discussed, and areas for which additional research is needed are presented.
摘要：
肾脏疾病：改善全球结果（KDIGO）2022慢性肾脏疾病（CKD）糖尿病管理临床实践指南代表了KDIGO2020指南的重点更新。该指南针对治疗糖尿病和CKD患者的临床医生的广泛受众。根据新证据更新建议的主题领域包括第1章：糖尿病和CKD患者的综合护理和第4章：2型糖尿病（T2D）和CKD患者的降糖治疗。前几章关于糖尿病和CKD患者血糖监测和目标的内容（第2章），糖尿病和CKD患者的生活方式干预（第3章），糖尿病和CKD患者的管理方法(第5章)已被认为是当前的，没有改变。本指南更新是根据明确的证据审查和评估过程制定的。治疗方法和指南建议基于对相关研究的系统回顾和对证据质量的评估，建议的强度遵循“建议评估分级”，开发和评估“(等级)方法。讨论了证据的局限性，并提出了需要进一步研究的领域。
